This is a non-core endpoint: only basic statistics are computed.
Malignant neoplasm of adrenal gland
C3_ADRENAL_GLAND
adrenal gland neoplasm: A neoplasm (disease) that involves the adrenal gland.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
151 |
4. Check minimum number of eventsNone |
151 |
5. Include endpointsNone |
151 |
6. Filter based on genotype QC (FinnGen only) |
142 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of adrenal gland
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of adrenal gland, including Hilmo
- Malignant neoplasm of endocrine gland
- Solid cancers, helper endpoint
- Malignant neoplasm
- Any event in cancer register
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 142 | 71 | 71 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | 57.85 | 54.06 | 61.64 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 151
- Matched controls
- 1510
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D44.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Adrenal gland
582.3
114.1
100
5
130
Kela drug reimbursment
Malignant tumour
+∞
75.5
66
*
C74.0
ICD-10 Finland
Malignant neoplasm: Cortex of adrenal gland
+∞
69.2
61
*
H02AB09
ATC
hydrocortisone; systemic
31.1
68.5
49
23
BCA31
NOMESCO Finland
Endoscopic unilateral adrenalectomy
356.0
67.1
63
*
C74.1
ICD-10 Finland
Malignant neoplasm: Medulla of adrenal gland
+∞
52.1
47
*
TPH07
NOMESCO Finland
Cathetrisation of artery
12.1
48.1
62
82
E27.5
ICD-10 Finland
Adrenomedullary hyperfunction
+∞
45.1
41
*
C74.9
ICD-10 Finland
Malignant neoplasm: Adrenal gland, unspecified
+∞
45.1
41
*
8700/3-C74.9
ICD-O-3
Pheochromocytoma, NOS, of adrenal gland, NOS
+∞
42.8
39
*
BCA30
NOMESCO Finland
Unilateral adrenalectomy
+∞
42.8
39
*
JN4BD
NOMESCO Finland
Extensive body CT
16.6
37.9
35
27
8370/3-C74.0
ICD-O-3
Adrenal cortical carcinoma of cortex of adrenal gland
+∞
35.9
33
*
JN4AD
NOMESCO Finland
Body CT examination
15.3
33.5
32
26
8700/3-C74.1
ICD-O-3
Pheochromocytoma, NOS, of medulla of adrenal gland
+∞
32.5
30
*
L01XX23
ATC
mitotane; oral
+∞
31.3
29
*
D35.0
ICD-10 Finland
Benign neoplasm: Adrenal gland
58.5
31.3
36
8
A03FA01
ATC
metoclopramide; systemic, rectal
8.0
30.6
53
96
JN3AD
NOMESCO Finland
Abdominal CT examination
7.9
23.7
38
62
A04AA02
ATC
granisetron; systemic, transdermal
269.2
23.3
23
*
H02AB02
ATC
dexamethasone; systemic
40.6
22.0
27
8
A04AA01
ATC
ondansetron; systemic, rectal
22.6
21.5
31
17
H02AA02
ATC
fludrocortisone; oral
127.8
21.2
22
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
19.6
19.3
29
18
WX402
NOMESCO Finland
General anaesthesia
4.9
18.9
56
161
ZXE20
NOMESCO Finland
More than three and less than five hours
5.5
17.5
41
96
WX408
NOMESCO Finland
General anesthesy, balanced
4.4
17.4
63
210
XW000
NOMESCO Finland
Bone marrow biopsy
23.5
17.1
24
12
9500/3-C74.1
ICD-O-3
Neuroblastoma, NOS, of medulla of adrenal gland
+∞
17.0
16
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
7.9
16.7
25
37
A49.9
ICD-10 Finland
Bacterial infection, unspecified
6.5
16.7
31
58
N02AA05
ATC
oxycodone; systemic
5.5
16.6
38
87
WZC00
NOMESCO Finland
Treatment plan or consultation
4.1
16.1
69
258
ZXE10
NOMESCO Finland
More than one and less than three hours
4.0
16.0
80
332
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
14.8
14
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
14.8
14
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
13.7
13
*
JN3CG
NOMESCO Finland
Extensive MRI examination of abdomen with high intensity magnet
153.2
13.7
14
*
B01AB05
ATC
enoxaparin; parenteral
3.7
13.4
61
233
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.1
12.9
44
137
Z51.5
ICD-10 Finland
Palliative care
16.3
12.7
20
14
L03AA02
ATC
filgrastim; parenteral
+∞
12.7
12
*
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
+∞
12.7
12
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.4
12.6
85
413
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
15.2
12.4
20
15
B01AB10
ATC
tinzaparin; parenteral
5.7
12.2
25
51
BC1CD
NOMESCO Finland
Very extensive CT of adrenal glands
51.1
12.1
14
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
11.6
11
*
BC5AQ
NOMESCO Finland
Chromaffine tissue SPECT with low dose CT
+∞
11.6
11
*
XX3DW
NOMESCO Finland
Time consuming IT work
9.7
11.0
22
26
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
30.6
10.9
14
5
H03AA01
ATC
levothyroxine sodium; systemic
3.5
10.9
48
176
WZC30
NOMESCO Finland
Teaching
4.1
10.8
35
104
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
10.5
10
*
BC1AD
NOMESCO Finland
CT of adrenal glands
35.3
10.5
13
*
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
20.6
10.5
15
8
JN4CD
NOMESCO Finland
Very extensive body CT
21.9
10.0
14
7
ZX120
NOMESCO Finland
Intravenous
5.3
9.6
21
45
E24.9
ICD-10 Finland
Cushing syndrome, unspecified
106.4
9.5
10
*
105
Kela drug reimbursment
Adrenal cortical hypofunction
+∞
9.5
9
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.8
9.4
33
103
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.3
9.2
44
168
WW500
NOMESCO Finland
Blood transfusion
13.7
9.1
15
12
JN3BD
NOMESCO Finland
Extensive abdominal CT
4.5
9.0
24
61
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.0
9.0
53
229
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
53.1
8.8
10
*
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
17.6
8.7
13
8
L01BC06
ATC
capecitabine; oral
+∞
8.4
8
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
8.4
8
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
8.4
8
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
8.4
8
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
8.4
8
*
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
+∞
8.4
8
*
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
4.6
8.3
21
51
J01MA12
ATC
levofloxacin; systemic
3.3
8.2
37
136
Z31.5
ICD-10 Finland
Genetic counselling
6.6
8.0
20
34
ZXD10
NOMESCO Finland
Scheduled procedure
2.7
7.9
70
370
JN3DG
NOMESCO Finland
Very extensive MRI examination with high intensity magnet
47.5
7.8
9
*
TPX10
NOMESCO Finland
Implantation of vascular injection port
14.3
7.5
12
9
L03AA13
ATC
pegfilgrastim; parenteral
84.0
7.5
8
*
N02AA01
ATC
morphine; systemic, rectal
84.0
7.5
8
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
84.0
7.5
8
*
8010/3-C74.9
ICD-O-3
Carcinoma, NOS, of adrenal gland, NOS
+∞
7.3
7
*
E27.1
ICD-10 Finland
Primary adrenocortical insufficiency
+∞
7.3
7
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
7.3
7
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
7.3
7
*
Z85.8
ICD-10 Finland
Personal history of malignant neoplasms of other organs and systems
+∞
7.3
7
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
7.3
7
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
7.3
7
*
2533
FHL
Unilateral removal of additional egg
+∞
7.3
7
*
WD225
NOMESCO Finland
Demanding therapy of methastized malignancy with hormones
+∞
7.3
7
*
XX9AN
NOMESCO Finland
Complementary isotope examination or additional picture
+∞
7.3
7
*
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
7.3
7
*
A04AD12
ATC
aprepitant; systemic
+∞
7.3
7
*
ZXE00
NOMESCO Finland
One hour or less
2.6
7.3
70
381
Z2221
NOMESCO Finland
Medical doctor
2.7
7.0
51
243
WF002
NOMESCO Finland
Radical radiotherapy
42.0
6.8
8
*
R11
ICD-10 Finland
Nausea and vomiting
3.5
6.8
25
80
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
10.7
6.7
12
12
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
8.8
6.5
13
16
BC5AN
NOMESCO Finland
Chromaffine and adrenergic tissue isotope imaging (MIBG)
+∞
6.3
6
*
116
Kela drug reimbursment
Prostate cancer
+∞
6.3
6
*
BC1BD
NOMESCO Finland
Extensive CT of adrenal glands
+∞
6.3
6
*
Y77
ICPC
Malignant neoplasm prostate
+∞
6.3
6
*
8370/3-C74.9
ICD-O-3
Adrenal cortical carcinoma of adrenal gland, NOS
+∞
6.3
6
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.8
6.3
20
58
ZXE06
NOMESCO Finland
Procedure duration 50 to 59 minutes
5.7
6.2
17
33
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
13.3
6.2
10
8
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
76
20
75.49
131.00
4.5
1.2
—
—
nmol/l
—
0
0
56
6
146.47
55.38
4.1
2.3
5.57
6.30
nmol/l
—
56
6
42
11
52.16
35.70
1.2
1.2
—
—
—
0
0
27
5
65.15
23.96
9.0
1.6
26.99
14.66
ug/l
—
27
5
106
465
5.29
21.22
4.2
2.4
—
—
—
0
0
108
528
4.67
17.57
16.7
8.2
1.20
1.22
mmol/l
1.67
84
464
38
95
5.01
14.87
7.3
10.4
0.97
1.15
mmol/l
0.11
33
79
32
69
5.62
14.80
6.7
3.7
1.24
1.22
mmol/l
0.86
32
58
61
236
3.66
13.07
4.4
2.0
—
—
—
0
0
27
58
5.45
12.45
1.6
1.2
—
—
—
0
0
71
313
3.39
12.24
4.4
3.4
0.25
0.24
e6/l
0.03
60
224
44
148
3.78
11.45
2.3
1.8
—
—
—
0
0
36
105
4.19
11.42
2.0
1.9
—
—
—
0
0
79
387
3.18
11.18
4.2
3.5
—
—
—
0
0
36
107
4.10
11.12
1.9
1.8
—
—
—
0
0
33
97
4.07
10.30
2.2
2.9
0.23
0.21
g/l
0.73
28
88
32
95
4.01
9.83
4.5
2.9
—
—
—
0
0
87
475
2.96
9.77
11.1
12.2
1.10
1.27
inr
1.84
39
144
107
675
3.01
8.85
27.1
6.6
4.03
4.14
e9/l
0.20
98
579
14
11
13.88
8.56
1.8
1.5
—
—
—
0
0
17
22
8.56
8.13
1.8
1.8
—
—
—
0
0
17
23
8.18
7.93
1.7
1.7
—
—
—
0
0
32
114
3.29
7.41
25.0
14.3
24.95
24.82
mmol/l
0.07
32
114
13
14
10.04
6.94
1.7
1.2
—
—
—
0
0
15
22
7.44
6.71
2.5
2.5
35.20
22.73
u/ml
—
10
15
10
7
15.17
6.49
1.5
1.1
—
—
—
0
0
12
13
9.91
6.42
1.5
2.0
—
—
—
0
0
12
13
9.91
6.42
1.5
2.0
—
—
—
0
0
17
44
4.23
6.18
3.9
4.0
102.41
86.36
%
1.69
17
44
13
19
7.37
5.88
1.8
1.3
—
—
—
0
0
9
7
13.56
5.65
6.3
5.1
—
—
—
0
0
14
25
6.06
5.53
1.4
1.3
—
—
—
0
0
37
169
2.58
5.38
2.4
2.6
13.44
14.09
umol/l
0.19
37
161
12
19
6.76
5.19
1.6
1.8
—
—
—
0
0
12
19
6.76
5.19
1.6
1.8
—
—
—
0
0
119
903
2.50
5.15
6.2
3.5
14.07
14.72
pmol/l
1.89
110
821
17
51
3.63
5.05
1.7
1.8
—
—
—
0
0
14
30
5.03
4.82
1.1
1.3
—
—
—
0
0
49
267
2.24
4.77
2.3
2.2
2.81
2.83
mg/l
0.03
44
230
13
31
4.49
4.12
1.5
2.1
176.25
279.00
u/ml
—
8
9
11
22
5.30
4.09
3.4
4.1
4.99
4.89
kpa
0.13
11
22
13
32
4.34
4.01
1.5
2.1
—
—
—
0
0
104
785
2.04
3.98
4.1
3.5
81.58
45.30
u/l
2.89
97
743
7
8
9.10
3.81
4.9
2.0
757.14
697.50
e6/l
—
7
8
10
20
5.27
3.76
1.2
3.4
—
—
—
0
0
37
199
2.14
3.63
4.1
3.4
1.39
2.35
e6/l
0.38
20
111
7
9
8.09
3.60
1.3
1.4
—
—
—
0
0
38
208
2.11
3.56
3.9
3.0
0.28
0.81
e6/l
2.56
20
120
6
6
10.34
3.53
2.8
1.5
5.75
4.47
nmol/l
—
6
6
9
18
5.24
3.43
2.7
4.2
57.33
57.94
%
—
9
18
7
10
7.27
3.40
1.9
1.3
—
—
—
0
0
8
14
5.97
3.39
1.1
1.1
—
—
—
0
0
9
19
4.97
3.29
1.4
1.3
—
—
—
0
0
131
1112
2.34
3.24
6.0
4.2
1.84
1.97
mu/l
0.61
121
1013
11
30
3.87
3.16
1.5
2.1
—
—
—
0
0
8
16
5.21
3.09
1.8
1.4
—
—
—
0
0
8
16
5.21
3.09
1.1
1.4
—
—
—
0
0
10
26
4.04
3.04
1.8
2.0
—
—
—
0
0
8
18
4.63
2.83
1.4
1.5
—
—
—
0
0
16
68
2.51
2.66
4.2
2.9
63.38
66.76
ml/min/173m2
—
8
21
6
11
5.63
2.57
2.3
1.2
—
—
—
0
0
106
865
1.76
2.55
4.8
4.2
16.02
10.74
mm/h
1.93
99
800
8
22
3.78
2.40
1.1
1.3
—
—
—
0
0
121
1038
1.83
2.31
29.8
9.7
83.20
83.14
ml/min/173m2
0.01
107
812
5
9
5.70
2.23
1.8
1.3
—
—
—
0
0
5
10
5.13
2.08
1.8
1.4
—
—
—
0
0
5
10
5.13
2.08
1.8
1.0
—
—
—
0
0
33
207
1.76
2.02
4.6
3.3
188.44
198.10
ng/l
0.03
25
150
7
21
3.44
1.99
1.1
1.3
—
—
—
0
0
7
21
3.44
1.99
1.1
1.3
—
—
—
0
0
5
11
4.66
1.95
1.0
1.0
—
—
—
0
0
5
12
4.27
1.84
1.0
1.0
—
—
—
0
0
11
53
2.16
1.42
1.8
1.8
—
—
—
0
0
36
254
1.55
1.40
2.7
1.9
1.18
0.89
mg/l
0.44
24
193
69
565
1.41
1.25
4.0
3.6
0.00
0.00
estimate
-0.00
23
91
68
556
1.41
1.24
5.9
5.2
0.00
0.00
estimate
-0.00
26
93
38
283
1.46
1.14
3.8
3.6
0.00
0.00
estimate
-0.00
23
92
7
30
2.40
1.14
1.7
1.2
—
—
—
0
0
7
30
2.40
1.14
1.3
2.0
—
—
—
0
0
52
413
1.40
1.10
2.0
1.9
86.60
93.88
pmol/l
0.51
24
195
5
21
2.43
1.10
2.4
2.3
122.80
132.36
g/l
—
5
14
67
557
1.36
1.07
4.0
3.6
0.00
0.01
estimate
0.50
26
107
131
1223
1.54
0.99
31.1
11.0
30.54
21.42
mg/l
2.32
119
911
13
78
1.73
0.95
2.0
2.1
—
—
—
0
0
10
55
1.88
0.94
40.3
4.6
0.66
0.62
%
—
10
55
23
314
0.68
0.89
1.3
1.5
0.86
2.84
u/ml
—
7
70
51
417
1.34
0.88
4.2
3.5
25.45
50.88
ng/l
1.74
33
280
13
81
1.66
0.84
1.3
1.2
85.00
102.97
iu/ml
—
7
31
6
32
1.91
0.82
2.2
1.6
—
—
—
0
0
6
32
1.91
0.82
1.3
1.4
1.10
0.68
nmol/l
—
6
27
7
124
0.54
0.82
14.7
5.5
—
—
—
0
0
6
34
1.80
0.77
2.0
1.7
—
—
—
0
0
25
187
1.40
0.74
2.2
1.7
1364.88
1138.11
nmol/l
0.48
18
141
7
39
1.83
0.73
1.7
1.1
—
—
—
0
0
51
428
1.29
0.72
3.8
3.5
—
—
—
0
0
5
28
1.81
0.67
1.0
1.5
—
—
—
0
0
5
28
1.81
0.67
1.2
1.2
—
—
—
0
0
28
221
1.33
0.61
3.4
2.6
1.09
0.75
ug/l
0.57
19
138
7
111
0.61
0.61
1.4
1.7
—
—
—
0
0
0
20
0.00
0.61
0.0
1.0
—
18.91
—
0
20
116
1094
1.26
0.54
4.8
3.9
1.46
1.28
mmol/l
1.33
107
1014
10
67
1.53
0.51
2.2
1.8
—
—
—
0
0
44
379
1.23
0.49
4.8
3.7
3.80
2.00
ug/l
0.62
36
342
17
130
1.35
0.46
2.1
2.2
—
—
—
0
0
7
50
1.42
0.45
2.0
1.6
—
—
—
0
0
38
328
1.21
0.42
2.6
3.1
1761.10
1296.90
ng/l
0.29
29
272
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
119
1138
1.22
0.40
4.8
4.4
4.76
4.63
mmol/l
0.61
110
1070
121
1160
1.22
0.39
5.1
4.9
2.75
2.76
mmol/l
0.05
111
1084
18
144
1.28
0.37
2.1
2.3
—
—
—
0
0
6
42
1.45
0.36
2.8
1.2
—
—
—
0
0
7
53
1.34
0.31
1.6
1.8
—
132.00
—
0
5
16
193
0.81
0.28
1.4
1.2
6.46
10.41
u/ml
—
5
76
117
1131
1.15
0.26
4.8
4.3
1.47
1.45
mmol/l
0.19
107
1055
39
352
1.15
0.26
4.6
3.8
30.05
63.11
mg/mmol
0.28
26
225
5
37
1.36
0.24
1.2
1.6
—
0.08
—
0
9
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
24
262
0.90
0.13
1.5
2.0
—
—
—
0
0
6
71
0.84
0.08
1.0
1.4
—
—
—
0
0
20
214
0.92
0.07
1.3
1.3
81.08
38.60
iu/ml
—
5
64
32
305
1.06
0.07
3.9
3.4
22.80
24.32
%
0.11
18
141
83
817
1.04
0.04
3.4
3.3
—
—
—
0
0
17
167
1.02
0.00
1.2
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
557.29
—
0
7
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
59.57
—
0
7
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
5
0.00
-0.00
0.0
3.2
—
122.60
—
0
5
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
6.0
—
162.34
—
0
5
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_ADRENAL_GLAND – Malignant neoplasm of adrenal gland
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).